Consequently, the development of novel CDK-2 inhibitors has drawn the attention of the research community because of the expected activity of these compounds against a wide range of cancer cell lines (Davies et al., 2002; Knockaert et al., 2002; Oudah et al., 2019). This evidence concerns the gene CDK2 and cancer.